Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setback

Cytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug could expand its addressable patient pool, potentially doubling the market size for the company.

The success comes after a previous effort by Bristol Myers to develop a treatment for the same condition fell short, highlighting Cytokinetics' progress in the competitive HCM space.

The company said the trial outcome strengthens its position with investors and may accelerate further development and commercial plans for the therapy.